-
Mashup Score: 15Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial - 1 year(s) ago
AbstractAims. An improved understanding of the pathophysiology of trastuzumab-mediated cardiotoxicity is required to improve outcomes of patients with human epi
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial - 1 year(s) ago
AbstractAims. An improved understanding of the pathophysiology of trastuzumab-mediated cardiotoxicity is required to improve outcomes of patients with human epi
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @FeliceGragnano: Phenotyping #trastuzumab-mediated cardiotoxicity: the MANTICORE trial #EHJPharmacotherapy 💊⤵️ https://t.co/LqNLIY0ybF…
-
-
Mashup Score: 2Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer - 1 year(s) ago
Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. AntimĂĽllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment–induced gonadotoxicity. Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial…
Source: JNCCNCategories: Hem/Oncs, Latest HeadlinesTweet-
Important start of 2023 with our #NeoALTTO gonadotoxicity analysis: weekly paclitaxel + #trastuzumab should not be considered completely gonadal safe...proper #oncofertility counseling is mandatory also in these women @OncoAlert #bcsm #BreastCancer #HER2 https://t.co/wRKskxb5n1 https://t.co/ecvu1x9gii
-
-
Mashup Score: 0Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rate, Is Cost Neutral in HER2+ Breast Cancer in Real-World Setting - 1 year(s) ago
Neoadjuvant chemotherapy with dual HER2-blockade of pertuzumab and trastuzumab is well tolerated and increases the rate of pathological complete response in patients with HER2-positive breast cancer compared with regimens that contain trastuzumab only, while being neutral on drug cost.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant chemo w/ dual HER2-blockade of #pertuzumab and #trastuzumab is well tolerated and increases the rate of pCR in patients with HER2+ breast cancer compared with regimens that contain trastuzumab only, while being neutral on drug cost. #bcsm https://t.co/arMPAlURaR
-
-
Mashup Score: 0Real-world Data Confirm Safety Profile for Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer - 1 year(s) ago
The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The safety profile for the combination of #tucatinib, #trastuzumab, and #capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2+ metastatic breast cancer. #bcsm https://t.co/Tcy8HmrmPD https://t.co/lwzaiaWOW2
-
-
Mashup Score: 0Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rate, Is Cost Neutral in HER2+ Breast Cancer in Real-World Setting - 1 year(s) ago
Neoadjuvant chemotherapy with dual HER2-blockade of pertuzumab and trastuzumab is well tolerated and increases the rate of pathological complete response in patients with HER2-positive breast cancer compared with regimens that contain trastuzumab only, while being neutral on drug cost.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant chemo w/ dual HER2-blockade of #pertuzumab and #trastuzumab is well tolerated and increases the rate of pCR in patients with HER2+ breast cancer compared with regimens that contain trastuzumab only, while being neutral on drug cost. #bcsm https://t.co/FNeZ5bGPsa
-
-
Mashup Score: 4Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy: - 1 year(s) ago
Central Illustration
Source: JACC: CardioOncologyCategories: Expert Picks, Latest HeadlinesTweet-
What is the long-term trajectory of RV systolic function in women with breast cancer who receive #doxorubicin and/or #trastuzumab? Find out in this #JACCCardioOnc Research Letter from @BiniyamD et al. https://t.co/HaMqaoSkqv #CardioOnc #BCsm #CardioTwitter https://t.co/DfytZ17nRN
-
-
Mashup Score: 0Real-world Data Confirm Safety Profile for Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer - 1 year(s) ago
The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The safety profile for the combination of #tucatinib, #trastuzumab, and #capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic #breastcancer. #Bcsm https://t.co/Z1QnDozRrj
-
-
Mashup Score: 0Dr Debra Patt Highlights Payer, Education Considerations in Use of Trastuzumab Deruxtecan for HER2-Low Breast Cancer - 2 year(s) ago
At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Dr Debra Patt (@dapattmd) Highlights #Payer, Education Considerations in Use of #Trastuzumab Deruxtecan for HER2-Low #BreastCancer. #PCOC2022 https://t.co/CpzL1N8gOA https://t.co/NaEMhUTW5h
-
-
Mashup Score: 1NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK - PubMed - 2 year(s) ago
Neuregulins are a family of growth-promoting peptides known to be important in neural and mesenchymal tissue development. Targeted disruption of neuregulin (NRG)-1 or one of two of its cognate receptors, ErbB2 or ErbB4, results in embryonic lethality because of failure of the heart to develop. Altho …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Neuregulin-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK https://t.co/Ufh6eD7zbz #trastuzumab #BreastCancer #heartfailure #MedTwitter #Cardiotwitter #Cardiology #CancerResearch
-
RT @FeliceGragnano: Phenotyping #trastuzumab-mediated cardiotoxicity: the MANTICORE trial #EHJPharmacotherapy 💊⤵️ https://t.co/LqNLIY0ybF…